The rising interest in GLP-1 agonists for metabolic conditions has sparked a question about application forms : transdermal systems versus tablets . Usually , GLP-1 drugs were solely available in oral form, but the introduction of transdermal delivery offers a alternative trump glp 1 announcement option . Transdermal systems might suit individuals